MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-11-2026
Minerva Neurosciences Operating Expenses 2011-2026 | NERV
Annual Operating Expenses Minerva Neurosciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.1 M | 21.8 M | 23.1 M | 25.2 M | 45.4 M | 39.3 M | 75.9 M | 51.7 M | 41.2 M | 30.2 M | 26.1 M | 54.9 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 75.9 M | 15.1 M | 37.5 M |
Quarterly Operating Expenses Minerva Neurosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.84 M | 3.37 M | 3.9 M | - | 4.37 M | 6.28 M | 6.68 M | - | 6.08 M | 4.52 M | 5.35 M | - | 5.21 M | 6.97 M | 7.99 M | - | 7.52 M | 8.96 M | 7.51 M | - | 8.09 M | 11.7 M | 12.3 M | - | 14.3 M | 12.9 M | 16.3 M | - | 12.4 M | 12.9 M | 12.7 M | - | 11.4 M | 9.75 M | 10.5 M | - | 8.23 M | 4.96 M | 7.76 M | - | 5.7 M | 6.33 M | 5.88 M | - | 27.2 M | 17.6 M | 2.62 M | - | 482 K | 379 K | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 27.2 M | 379 K | 8.42 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
88.1 M | - | 1052.0 % | $ 415 M |  USA |
 |
Verastem
VSTM
|
147 M | $ 5.04 | -4.73 % | $ 349 M | USA |
 |
Voyager Therapeutics
VYGR
|
172 M | $ 3.96 | -4.12 % | $ 232 M | USA |
 |
VistaGen Therapeutics
VTGN
|
56.5 M | $ 0.57 | -5.87 % | $ 17.6 M | USA |
 |
Aeterna Zentaris
AEZS
|
23 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
29.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
163 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
50.6 M | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
427 M | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
5.21 K | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
98.7 M | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
206 M | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
854 M | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
24.4 M | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
26 M | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
140 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
24.6 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
141 M | $ 12.41 | -11.1 % | $ 1.88 B | USA |
 |
Wave Life Sciences Ltd.
WVE
|
258 M | $ 6.37 | 2.66 % | $ 1.07 B |  Singapore |
 |
Xenetic Biosciences
XBIO
|
5.81 M | $ 2.72 | -2.86 % | $ 4.63 M | USA |
 |
XBiotech
XBIT
|
42.5 M | $ 2.27 | -1.73 % | $ 69.2 M | USA |
 |
Xenon Pharmaceuticals
XENE
|
279 M | $ 54.48 | -1.89 % | $ 4.24 B | Canada |
 |
Xeris Pharmaceuticals
XERS
|
94.7 M | $ 5.4 | -3.05 % | $ 866 M | USA |
 |
X4 Pharmaceuticals
XFOR
|
87.6 M | $ 4.04 | -6.26 % | $ 171 M | USA |
 |
Xencor
XNCR
|
303 M | $ 11.42 | -7.23 % | $ 848 M | USA |
 |
XOMA Corporation
XOMA
|
40.8 M | $ 30.17 | -1.18 % | $ 364 M | USA |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
22nd Century Group
XXII
|
8.43 M | $ 2.41 | -18.03 % | $ 444 K | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
142 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
120 M | - | - | $ 3.74 B | USA |
 |
Zai Lab Limited
ZLAB
|
212 M | $ 18.0 | 2.8 % | $ 19.7 B | China |
|
Enlivex Therapeutics Ltd.
ENLV
|
19.3 M | $ 1.05 | -3.67 % | $ 21.5 M | Israel |
 |
Enochian Biosciences
ENOB
|
189 M | - | - | $ 40.5 M | USA |